Clinical trial of MVI 816 in combination with a PD-1 pathway inhibitor for the treatment of prostate cancer.

Trial Profile

Clinical trial of MVI 816 in combination with a PD-1 pathway inhibitor for the treatment of prostate cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs MVI 816 (Primary) ; Pembrolizumab (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2016 According to a Madison Vaccines media release, this trial will guide expanded trials for treating late-stage cancers.
    • 08 Nov 2016 Interim results published in the Madison Vaccines Media Release.
    • 27 Oct 2016 According to a Madison Vaccines media release, data from this trial will be presented at the at the Society for Immunotherapy of Cancer annual meeting in November.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top